Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

In this real world cohort, tralokinumab for dupilumab nonresponders reduced body surface area and pruritus scores and eased ...

In patients with moderate-to-severe allergic asthma, tezepelumab yields the greatest reduction in exacerbations among ...

Dupilumab reduces mucus plugging and improves lung function in patients with moderate-to-severe type 2 asthma.

HealthDay News — Dupilumab reduces mucus plug scores and improves lung function in patients with moderate-to-severe asthma and high baseline mucus plug scores, according to a study published online ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

Germany’s Formycon has announced details of one of its previously undisclosed development projects in the shape of FYB208, a ...

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk. “Dupilumab controls symptoms ...